NeoGenomics, Inc. (NASDAQ:NEO) Receives $20.30 Average Price Target from Analysts

Shares of NeoGenomics, Inc. (NASDAQ:NEO) have been given a consensus recommendation of “Moderate Buy” by the eleven brokerages that are currently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a hold rating and nine have issued a buy rating on the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $20.30.

Several research analysts have weighed in on the company. Jefferies Financial Group assumed coverage on NeoGenomics in a research report on Tuesday, December 10th. They issued a “buy” rating and a $22.00 price objective on the stock. Benchmark downgraded shares of NeoGenomics from a “buy” rating to a “hold” rating in a report on Monday, January 13th. Bank of America increased their price target on shares of NeoGenomics from $18.00 to $19.00 and gave the company a “neutral” rating in a research report on Friday, December 13th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $19.00 price objective on shares of NeoGenomics in a research report on Friday, January 10th.

Insider Activity at NeoGenomics

In related news, General Counsel Alicia C. Olivo sold 5,175 shares of the business’s stock in a transaction that occurred on Friday, November 15th. The shares were sold at an average price of $15.36, for a total transaction of $79,488.00. Following the completion of the transaction, the general counsel now owns 37,129 shares of the company’s stock, valued at approximately $570,301.44. The trade was a 12.23 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 1.30% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Versant Capital Management Inc grew its position in NeoGenomics by 174.9% during the fourth quarter. Versant Capital Management Inc now owns 1,795 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 1,142 shares during the last quarter. Quarry LP purchased a new stake in NeoGenomics during the third quarter valued at about $40,000. Blue Trust Inc. grew its stake in shares of NeoGenomics by 42.3% during the third quarter. Blue Trust Inc. now owns 3,318 shares of the medical research company’s stock valued at $46,000 after buying an additional 987 shares during the last quarter. Canada Pension Plan Investment Board purchased a new position in shares of NeoGenomics in the second quarter worth about $57,000. Finally, KBC Group NV increased its holdings in shares of NeoGenomics by 33.1% in the third quarter. KBC Group NV now owns 4,530 shares of the medical research company’s stock worth $67,000 after buying an additional 1,127 shares during the period. Hedge funds and other institutional investors own 98.50% of the company’s stock.

NeoGenomics Stock Performance

Shares of NEO stock opened at $14.18 on Friday. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.99 and a quick ratio of 1.91. The firm has a 50-day moving average of $16.64 and a 200-day moving average of $15.68. NeoGenomics has a one year low of $12.13 and a one year high of $19.11. The company has a market cap of $1.82 billion, a P/E ratio of -23.25 and a beta of 1.24.

NeoGenomics (NASDAQ:NEO) last posted its quarterly earnings data on Tuesday, November 5th. The medical research company reported $0.05 EPS for the quarter, beating the consensus estimate of $0.01 by $0.04. NeoGenomics had a negative net margin of 12.07% and a negative return on equity of 2.11%. The firm had revenue of $167.80 million during the quarter, compared to analyst estimates of $167.00 million. During the same quarter last year, the business posted ($0.06) EPS. The company’s revenue for the quarter was up 10.5% on a year-over-year basis. Equities research analysts forecast that NeoGenomics will post -0.16 EPS for the current fiscal year.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.